
Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India
‘Patent opposition’ seeks to ensure availability of affordable generics New Delhi/Geneva, 10 February, 2016—People living with HIV have opposed patent applications in India for two important HIV medicines, dolutegravir and cabotegravir. Médecins Sans Frontières/ Doctors






